Literature DB >> 3612650

Morbidity in systemic lupus erythematosus.

D D Gladman, M B Urowitz.   

Abstract

Over the past 30 years there has been an increase in the survival rate in systemic lupus erythematosus (SLE). As patients with SLE live longer, clinicians involved in their care are confronted with the longterm morbid complications that result either from previous SLE disease itself or as a complication of therapy. Our paper deals with the changing pattern of morbidity in SLE and specifically highlights 3 aspects: atherosclerosis, avascular necrosis and neuropsychological dysfunction. These must be considered as added features in the disease spectrum of SLE.

Entities:  

Mesh:

Year:  1987        PMID: 3612650

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  38 in total

1.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.

Authors:  M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

Review 2.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

Review 3.  Kidney disease in systemic lupus erythematosus.

Authors:  J E Balow
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

4.  Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study.

Authors:  M B Urowitz; D D Gladman; D Ibanez; Y Berliner
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 5.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

6.  Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine.

Authors:  J F Muñoz-Valle; M Vázquez-Del Mercado; S Ruiz-Quezada; E Oregón-Romero; R E Navarro-Hernández; J Ramírez-Barragán; G Martínez-Bonilla; G Bernard-Medina; B E Bastidas-Ramírez; B Ruiz-Madrigal; A Panduro
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

7.  The SLICC inception cohort for atherosclerosis.

Authors:  Murray B Urowitz; Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

8.  Peripheral vascular disease in patients with systemic lupus erythematosus.

Authors:  J McDonald; J Stewart; M B Urowitz; D D Gladman
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study.

Authors:  Mandana Nikpour; Dafna D Gladman; Dominique Ibanez; Paula J Harvey; Murray B Urowitz
Journal:  Arthritis Res Ther       Date:  2010-06-30       Impact factor: 5.156

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.